Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging

Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging

Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) have emerged as the leading causes of chronic liver disease-related mortality. The prevalence of NAFLD/NASH is expected to increase given the epidemics of obesity and type 2 diabetes mellitus. Old...

Full description

Saved in:
Bibliographic Details
Published in:Aging and disease Vol. 13; no. 4; pp. 1239 - 1251
Main Authors: Li, Yuan, Adeniji, Nia T, Fan, Weiguo, Kunimoto, Koshi, Török, Natalie J
Format: Journal Article
Language:English
Published: United States JKL International 01-08-2022
JKL International LLC
Subjects:
Aging
Complications and side effects
Development and progression
Fatty liver
Health aspects
Hepatoma
Liver cirrhosis
Physiological aspects
Review
Risk factors
United States
senescence
NAFLD
fibrosis
aging
liver
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) have emerged as the leading causes of chronic liver disease-related mortality. The prevalence of NAFLD/NASH is expected to increase given the epidemics of obesity and type 2 diabetes mellitus. Older patients are disproportionally affected by NASH and related complications such as progressive fibrosis, cirrhosis and hepatocellular carcinoma; however, they are often ineligible for liver transplantation due to their frailty and comorbidities, and effective medical treatments are still lacking. In this review we focused on pathways that are key to the aging process in the liver and perpetuate NAFLD/NASH, leading to fibrosis. In addition, we highlighted recent findings and cross-talks of normal and/or senescent liver cells, dysregulated nutrient sensing, proteostasis and mitochondrial dysfunction in the framework of changing metabolic milieu. Better understanding these pathways during preclinical and clinical studies will be essential to design novel and specific therapeutic strategies to treat NASH in the elderly.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2152-5250
2152-5250
DOI:10.14336/AD.2022.0318